495 related articles for article (PubMed ID: 29578580)
41. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
Engelbrecht I; Petzer JP; Petzer A
Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
[TBL] [Abstract][Full Text] [Related]
42. Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease.
Goudreau JL; Maraganore DM; Farrer MJ; Lesnick TG; Singleton AB; Bower JH; Hardy JA; Rocca WA
Mov Disord; 2002 Nov; 17(6):1305-11. PubMed ID: 12465073
[TBL] [Abstract][Full Text] [Related]
43. Functional monoamine oxidase B gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson's disease.
Löhle M; Mangone G; Wolz M; Beuthien-Baumann B; Oehme L; van den Hoff J; Kotzerke J; Reichmann H; Corvol JC; Storch A
Mov Disord; 2018 Sep; 33(9):1496-1501. PubMed ID: 30216543
[TBL] [Abstract][Full Text] [Related]
44. The COMT L allele modifies the association between MAOB polymorphism and PD in Taiwanese.
Wu RM; Cheng CW; Chen KH; Lu SL; Shan DE; Ho YF; Chern HD
Neurology; 2001 Feb; 56(3):375-82. PubMed ID: 11171904
[TBL] [Abstract][Full Text] [Related]
45. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.
Petzer JP; Castagnoli N; Schwarzschild MA; Chen JF; Van der Schyf CJ
Neurotherapeutics; 2009 Jan; 6(1):141-51. PubMed ID: 19110205
[TBL] [Abstract][Full Text] [Related]
46. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
Pahwa R
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
[TBL] [Abstract][Full Text] [Related]
47. Lack of effect of polymorphisms in dopamine metabolism related genes on imaging of TRODAT-1 in striatum of asymptomatic volunteers and patients with Parkinson's disease.
Lynch DR; Mozley PD; Sokol S; Maas NM; Balcer LJ; Siderowf AD
Mov Disord; 2003 Jul; 18(7):804-12. PubMed ID: 12815660
[TBL] [Abstract][Full Text] [Related]
48. Catechol-O-methyltransferase and monoamine oxidase B genes and susceptibility to sporadic Parkinson's disease in a Polish population.
Białecka M; Droździk M; Honczarenko K; Gawrońska-Szklarz B; Stankiewicz J; Dabrowska E; Kubisiak M; Kłodowska-Duda G; Opala G
Eur Neurol; 2005; 53(2):68-73. PubMed ID: 15753616
[TBL] [Abstract][Full Text] [Related]
49. Advanced Parkinson's disease treatment patterns in Italy: an observational study interim analysis.
Stocchi F; Barone P; Ceravolo R; De Pandis MF; Lopiano L; Modugno N; Padovani A; Pilleri M; Tessitore A; Zappia M
Ann Med; 2024 Dec; 56(1):2315226. PubMed ID: 38381654
[TBL] [Abstract][Full Text] [Related]
50. Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.
Regensburger M; Ip CW; Kohl Z; Schrader C; Urban PP; Kassubek J; Jost WH
J Neural Transm (Vienna); 2023 Jun; 130(6):847-861. PubMed ID: 36964457
[TBL] [Abstract][Full Text] [Related]
51. The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety.
de Beer AD; Legoabe LJ; Petzer A; Petzer JP
Bioorg Chem; 2021 Sep; 114():105130. PubMed ID: 34225162
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.
Müller T; Woitalla D; Muhlack S
Naunyn Schmiedebergs Arch Pharmacol; 2011 Jun; 383(6):627-33. PubMed ID: 21533995
[TBL] [Abstract][Full Text] [Related]
53. Relationships of Cerebrospinal Fluid Alzheimer's Disease Biomarkers and COMT, DBH, and MAOB Single Nucleotide Polymorphisms.
Babić Leko M; Nikolac Perković M; Klepac N; Švob Štrac D; Borovečki F; Pivac N; Hof PR; Šimić G
J Alzheimers Dis; 2020; 73(1):135-145. PubMed ID: 31771069
[TBL] [Abstract][Full Text] [Related]
54. Impact of COMT H108L, MAOB int 13 A>G and DRD2 haplotype on the susceptibility to Parkinson's disease in South Indian subjects.
Kumudini N; Umai A; Devi YP; Naushad SM; Mridula R; Borgohain R; Kutala VK
Indian J Biochem Biophys; 2013 Oct; 50(5):436-41. PubMed ID: 24772965
[TBL] [Abstract][Full Text] [Related]
55. Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment.
Espinoza S; Manago F; Leo D; Sotnikova TD; Gainetdinov RR
CNS Neurol Disord Drug Targets; 2012 May; 11(3):251-63. PubMed ID: 22483291
[TBL] [Abstract][Full Text] [Related]
56. Monoamine Oxidase B Inhibitors in Parkinson's Disease.
Dezsi L; Vecsei L
CNS Neurol Disord Drug Targets; 2017; 16(4):425-439. PubMed ID: 28124620
[TBL] [Abstract][Full Text] [Related]
57. A Systematic Review of Parkinson's Disease Pharmacogenomics: Is There Time for Translation into the Clinics?
Vuletić V; Rački V; Papić E; Peterlin B
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281267
[TBL] [Abstract][Full Text] [Related]
58. Treatment Strategies in Early Parkinson's Disease.
Marsili L; Marconi R; Colosimo C
Int Rev Neurobiol; 2017; 132():345-360. PubMed ID: 28554414
[TBL] [Abstract][Full Text] [Related]
59. COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease.
Lee MS; Kim HS; Cho EK; Lim JH; Rinne JO
Neurology; 2002 Feb; 58(4):564-7. PubMed ID: 11865133
[TBL] [Abstract][Full Text] [Related]
60. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
Deleu D; Northway MG; Hanssens Y
Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
